University of Wisconsin Milwaukee

UWM Digital Commons
Theses and Dissertations

August 2013

Metformin-Induced PEDF Expression Regulates
Cell Proliferation and Lipid Metabolism in Prostate
Cancer Cells
Miguel Angel Tolentino
University of Wisconsin-Milwaukee

Follow this and additional works at: https://dc.uwm.edu/etd
Part of the Cell Biology Commons, and the Medicine and Health Sciences Commons
Recommended Citation
Tolentino, Miguel Angel, "Metformin-Induced PEDF Expression Regulates Cell Proliferation and Lipid Metabolism in Prostate
Cancer Cells" (2013). Theses and Dissertations. 335.
https://dc.uwm.edu/etd/335

This Thesis is brought to you for free and open access by UWM Digital Commons. It has been accepted for inclusion in Theses and Dissertations by an
authorized administrator of UWM Digital Commons. For more information, please contact open-access@uwm.edu.

METFORMIN-INDUCED PEDF EXPRESSION
REGULATES CELL PROLIFERATION AND LIPID
METABOLISM IN PROSTATE CANCER CELLS

by

Miguel Tolentino

A Thesis Submitted in
Partial Fulfillment of the
Requirements for the Degree of
Master of Science
in Biomedical Sciences
at
The University of Wisconsin-Milwaukee
August 2013

ABSTRACT
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Prostate cancer (PCa) is one of the most common cancers in American males. A
high fat diet and obesity accelerate PCa progression and increase the 1risk of death from
disease. Epidemiological studies have indicated that PCa patients with type 2 diabetes
have higher mortality rates than PCa patients without diabetes. Type 2 diabetics who are
on metformin, a drug to control blood sugar levels, show a delay in PCa progression in
comparison with PCa patients with type 2 diabetes who are not on metformin. It has been
proposed that metformin inhibits proliferation via activation of AMP-activated protein
kinase (AMPK) or by blocking proliferation at the G0/G1 phase in the cell cycle with a
reduction in cyclin D1. However, the mechanism is still unclear, as these in vitro studies
used 5 mM metformin which is physiologically not attainable. AMPK is known to
stimulate lipolysis, the breakdown of triglycerides into fatty acids functions. As increased
lipid anabolism is known to promote PCa, the lipolysis produced by AMPK, during
metformin treatment, may also contribute to the anti-tumor activity of metformin.
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Pigment epithelium-derived factor (PEDF) is a glycoprotein with multiple
functions. Its expression is decreased in many cancer types, including PCa. Exogenous
PEDF treatment reduces prostate tumor growth, metastasis, and angiogenesis.
Interestingly, it has been reported that type 2 diabetes patients on metformin present with
higher serum levels of PEDF in comparison with healthy patients not on metformin.
In this work, I tested the hypothesis that one mechanism of metformin’s activity
may be via stimulation of PEDF. Metformin increased intracellular PEDF in LNCaP
cells, and extracellular PEDF in RWPE-1 and LNCaP cells. Metformin also reduced cell
proliferation and increased lipolysis in PCa cells at physiological obtainable doses (0.02
and 0.5 mM). I also observed that at these lower doses, metformin increased the
expression of cyclin D1 and AMPK, but at 5 mM doses reduced cyclin D1. Supporting
PEDF’s role in lipid metabolism, in PEDF KO prostate tissues there was less lipolytic
activity and altered triglyceride levels in comparison with wild type tissue. Overall, these
data support the hypothesis that metformin may act through PEDF.
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INTRODUCTION
Prostate cancer
Prostate cancer is a disease that affects older men. Epidemiological studies have
reported that 65% of prostate cancer patients are diagnosed over the age of 65 [1]. The
concern about prostate cancer has increased because it has become the second leading
cause of death by cancer after lung cancer in American men [2]. The prostate is a male
reproductive gland, approximately 4 cm in width, and is localized under the urinary
bladder, in front of the rectum. Its main function is the production of seminal fluid. The
prostate is constituted by three glandular regions called, the peripheral zone, central zone,
and transition zone. There is a fourth region which is not glandular called the anterior
fibromuscular

stroma

[3,

4].

Approximately

95%

of

prostate

cancers

are

adenocarcinomas, which are cancers that originate from the prostatic epithelial cells. Of
these 70% are localized in the peripheral zone, 15-20% in the central zone, and 10-15%
in the transitional zone [1, 4]. Cancers metastasize via the lymphphatic system and
through the bloodstream to reach distant sites, and in metastatic prostate cancer, common
sites of metastasis are the bone and brain [1, 4].
The initial stages of prostate cancer are asymptomatic. Most of the time,
symptoms are present only when the disease is in a very advanced stage. Some symptoms
include dysuria (pain during urination), slow stream of urine flow, incontinence, and
urine retention. Symptoms during metastasis include,
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pancytopenia (a reduction in the production of erythrocytes, white blood cells, and
platelets), anemia, weight loss, and leg pain [5].
The diagnosis of prostate cancer is often difficult. Digital rectal examination
(DRE) and the prostate specific antigen (PSA) blood test are the two main tests used to
identify prostate cancer. DRE possesses a low sensitivity with approximately 54%
accuracy. However, this test can detect prostate cancer in men with normal values of
PSA, and it is cheap, usually acceptable among patients, and can also detect benign
prostatic hyperplasia (BPH). PSA is the most common test used to detect, classify, and
monitor prostate cancer. The PSA blood test is an inexpensive test, with acceptance
among patients, and high sensitivity, but is not very specific. High levels of PSA can be
detected also in pathological conditions such as BPH and prostatitis [1]. If either of these
tests indicates the presence of cancer, then transrectal ultrasound imaging is used to guide
the acquisition of biopsy tissues from the prostate. Thus, to obtain an accurate diagnosis,
it is necessary to evaluate symptoms, medical history of the patient, and also use other
tests such as biopsy and histological examination. In cases where metastatic cancer is
suspected, X-rays, magnetic resonance imaging, computerized tomography scans, and
bone scans would also be used [1].
Once a tumor is diagnosed, it is characterized by stage and grade. For staging, the
tumor, node, metastasis (TNM) system is used. The TNM classification system depicts
the characteristics of the tumor (T), if the cancer has spread to the regional lymph nodes
(N), or if the cancer has metastasized (M) [1]. The tumor grading of prostate cancer is a
tool which relies on histologic assessment of the prostate tissue. The degree of
malignancy of a tumor can be determined according to its physical characteristics under
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the microscope. The Gleason score is the most common grading system to classify
prostate cancer. The Gleason system is based on the examination of prostate tissue
obtained by biopsy or following surgical removal of the prostate. In this system,
histological patterns are classified by the appearance of the glands and cells and scored
on a 1-5 scale. As prostate occurs in the glands and is heterogeneous, the Gleason score is
then based on the score obtained after the sum of the 2 most predominant patterns. As
general rule, a score under 6 is not considered cancer, while a score of 6 or above is
cancer, and a score at or above 7 indicates an aggressive cancer [6, 7].

Prostate cancer progression and angiogenesis
Prostate cancer begins as a consequence of irreparable damage in the DNA,
leading to both abnormal growth and cell functions. The carcinogenesis process involves
three phases: initiation, where the DNA damage is initiated; promotion, where DNA
damage produces cellular changes in prostate cells; and progression, where both an
increase in the number of cells and an abnormal performance occur [8].
For cancer progression and metastasis, it is necessary that the tumor induces its
own blood supply. In order to do this, the tumor uses a process called angiogenesis.
Angiogenesis is the formation of new vessels from existing vessels [9, 10]. This process
is regulated by multiple factors. In normal tissue, for example, there are proteins that
inhibit the angiogenic process. Conversely, angiogenesis can be activated by the presence
of pro-angiogenic factors such as vascular endothelial growth factor (VEGF), platelet
derived growth factor (PDGF), fibroblast growth factor (FGF-2), and interleukin-8 [9,
10]. The angiogenesis process in tumors can be blocked by the inhibition of these pro-
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angiogenic factors or introducing anti-angiogenic molecules, and thus could be a safe and
less toxic therapeutic strategy against cancer progression [9, 10]. It has been reported that
pigment epithelium-derived factor (PEDF), a multifunctional angiogenesis inhibitor, is
down-regulated in several cancers [11].

Pigment epithelium derived factor (PEDF)
PEDF is a 50 kDa glycoprotein that was identified in 1987 from cell conditioned
media from retinal pigment epithelial cells [12]. PEDF belongs to the serine protease
inhibitors (Serpin) family of proteins. The Serpins family includes two groups. Both
Serpin groups share similarities in structure; however, the first group possesses a region
called the reactive center loop which contains a region that interacts with the specific
protease. The second group does not have this motif and thus does not function as a
protease [13]. PEDF is a member of the second group, and some of this group’s functions
include hormone transport, molecular chaperone, and tumor suppression [13].
PEDF possesses four main functions: angiogenesis inhibition, promotion of
apoptotic activity, neuroprotective activity, and induction of cell differentiation. These
functions are cell type specific [14]. Two peptide regions (epitopes) that mediate many of
PEDF functions have been identified. The 44-residue fragment (residues 78-121) is
responsible for the anti-angiogenic and tumor cell apoptosis activities, while the 34residue fragment (residues 44-77) is responsible for the neuroprotective effect and cell
differentiation activity [12, 14, 15].
In the eye, PEDF promotes homeostasis and, in pathological conditions, it
promotes apoptosis in endothelial cells to avoid the aberrant formation of blood vessels
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[16]. Wang, et al, reported that exogenous PEDF treatment reduced proliferation of
human aortic smooth muscle cells (HASMCs) [17]. In fact, PEDF has presented a higher
anti-angiogenic effect than other angiogenesis inhibitors such as angiostatin,
thrombospondin-1, and endostatin [14]. In In vitro studies, it was found that PEDF blocks
cell cycle progression at the G0/G1 phase and reduces cyclin D1, cyclin E, CDK2, CDk4,
and p21 in endothelial cells [17]. It was shown in in vivo studies using athymic mice with
neuroblastomas that intratumoral injections of recombinant PEDF generated cell
differentiation and lead to the production of fewer malignant cells in histological samples
[18].

PEDF in prostate cancer
In the prostate, the gene that encodes PEDF, SERPINF1 plays a fundamental role
as a tumor suppressor gene. It has been found that PEDF knockout (KO) mice present
with epithelial cell hyperplasia and higher stromal microvessel density in the prostate as
compared to the prostate of wild type mice [19].
Doll, et al. has previously found that PEDF expression is down-regulated in
prostate cancer patient tissues, and is also down-regulated in three prostate cancer cell
lines (DU145, LNCaP, and PC-3) in comparison with a normal prostate epithelial cell
line [19]. Furthermore, the treatment of tumor xenografts with recombinant PEDF
reduced stromal vasculature and induced apoptosis [19]. In vitro, PEDF induced
apoptosis of prostate cancer cells, and also it has been found that PEDF is downregulated by androgens [19].
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Guan, et al, reported the use of an adenoviral vector to induce the overexpression
of PEDF in PC-3 cells. They found that overexpression of PEDF produced a reduction in
cell proliferation [20]. Moreover, microarray analysis showed that PEDF regulated genes
involved in signal transduction, proliferation, angiogenesis, and apoptosis [20]. In another
study, DU145 and PC-3 cells were treated with exogenous PEDF, and genes that were
up-regulated in both cell lines included a brain angiogenesis inhibitor, a binding adaptor
protein (adaptor-related protein complex 2, mu 1 subunit), and an apoptosis regulator
(growth arrest and DNA-damage-inducible, alpha). Genes that were down-regulated in
both cell lines included AMP-activated protein kinase (AMPK), ubiquitin specific
protease 6, and fibroblast growth factor 3 [21]. These data emphasize the multifunctional
nature of PEDF and its potential as a therapeutic target.

PEDF and lipid metabolism
It has been suggested that PEDF also plays a role in lipid metabolism. In a
published study, it was found that PEDF was synthetized in vitro by human primary
adipocytes obtained from lean or moderately overweight patients at a concentration of
130 ng/ml over 24 h from one million cells [22]. This concentration is relatively higher
compared to other molecules synthesized by the adipocytes such as adiponectin,
interleukin-6, or IL-8 [22]. In mouse models, an increase in serum levels of PEDF was
detected during obesity, while a reduction was observed during weight loss [23].
Moreover, it has been reported that type 1 diabetes patients with microvascular
complications and, also, type 2 diabetes patients present with higher serum levels of
PEDF in comparison with non-diabetic controls [24, 25]. In the adipose tissue, the anti-
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angiogenic PEDF maintains homeostasis and prevents over vascularization during
adipose tissue growth by the inhibition of angiogenic factors such as TNF-α, PDGF,
VEGF, and FGF-2 [23].
In hepatocytes, PEDF binds to adipose triglyceride lipase (ATGL) to stimulate the
breakdown of triglycerides [26, 27], and the lack of PEDF and/or ATGL produces lipid
accumulation [26]. These results indicate that PEDF participates in lipid metabolism;
however, the molecular pathway and precise role is not clear. In addition, the lipid
regulatory functions of PEDF have not been studied in prostate cancer cells.

Obesity, high fat diet, and prostate cancer
Epidemiological studies have reported that obesity and a high fat diet increase the
incidence and risk of death from disease in many cancer types, including esophageal,
colon, rectal, liver, gallbladder, pancreatic, renal, breast, and ovarian cancers [28]. In
prostate cancer, while obesity and a high fat diet do not increase the risk of disease, they
do increase the risk of death from disease [1]. Epidemiological studies have found that
obese prostate cancer patients have a higher mortality rate than patients of normal weight
[29]. The effect of a high fat diet, also called a Western diet, on prostate cancer can be
observed in epidemiological studies of Japanese and Chinese populations. The diet of
these Asian populations is characterized by high levels of fiber and low levels of fats, and
both populations present with low incidence of prostate cancer [30]. However, after
migration to the United States, both populations experience an increase in prostate cancer
incidence [30-32]. Studies in mouse models have shown that the consumption of a diet
with high levels of fat and cholesterol accelerates cancer progression and angiogenesis

8

[2]. For example, a high fat diet increases the cell growth of LNCaP cells in a xenograft
model [33]. On the other hand, a low fat diet and a high-fiber diet decrease the cellular
growth and increases apoptosis in LNCaP cells [34]. These data demonstrate that
environmental factors, such as a change in diet or other lifestyle changes (consumption of
drugs, alcohol, tobacco, etc.), affect prostate cancer.

Diabetes, metformin, and cancer
Obesity significantly increases the risk of a patient developing diabetes.
Epidemiological studies have indicated that diabetics have a higher risk of acquiring
cancer and also have a higher mortality rate than non-diabetic cancer patients [29, 35-37].
In prostate cancer, diabetes is associated with a worse prognosis and a higher mortality
rate than non-diabetic prostate cancer patients [29, 35]. Type 2 diabetes patients often
present with insulin resistance which leads to hyperinsulinemia [38]. As stated
previously, obesity increases the risk of developing some kinds of cancers, and insulin is
a hormone related with growth processes promoting cell proliferation. Thus, it has been
suggested that obesity combined with high levels of insulin produce a carcinogenic effect
[39].
Interestingly, cancer patients with type 2 diabetes on a drug called metformin
have shown a slower cancer progression [35, 39]. Metformin is a drug commonly used by
type 2 diabetes patients in order to control their blood sugar levels. It is absorbed into the
body within 1-3 hours after administration, and 90% is eliminated by the renal system
[40]. Metformin produces several different effects. It reduces circulating glucose levels
by decreasing the production of glucose by the liver. It also reduces the resistance to
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insulin by increasing the uptake of glucose by muscles and adipose tissue, resulting in
normalization of insulin levels [39]. The effect of metformin on reducing glucose levels
is observed only in patients with diabetes and/or insulin resistance, but metformin does
not have an effect on healthy people [40].
It has been reported that metformin decreases the incidence of prostate, pancreatic
and colon cancers, and decreases the progression of prostate, breast, pancreatic, colon,
lung, and ovarian cancers [35, 39, 41]. Epidemiological studies compared the mortality
rate in diabetic prostate cancer patients on insulin, sulfonylureas (sulfonylureas increase
insulin secretion) or metformin, and in non-diabetic prostate cancer patients. The results
showed that diabetic patients on insulin or sulfonylureas therapy had a higher mortality
rate in comparison to non-diabetic patients, and patients on metformin showed a
reduction in mortality [35, 36]. Thus, it has been suggested that metformin may possess
anticancer effect in prostate cancer; however, its molecular pathways have not been
studied completely.
As explained above, there is a decrease in PEDF expression in prostate tissue [19]
and in circulating levels in prostate cancer patients [42]. In contrast, obese type 2 diabetes
patients have high serum levels of PEDF [25], which appears to correlate most closely
with insulin resistance [22]. However, the tissue source of this change in circulating
PEDF is currently unknown, and studies in obese prostate cancer patients have not been
reported. While some studies indicate that PEDF participates in the resistance to insulin
[22], other studies indicate that the increase in the PEDF levels is a compensatory
response to high insulin levels and insulin resistance [23]. Thus, further studies are
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necessary to elucidate the PEDF’s role in diabetes and to identify the tissue that produces
the high values of PEDF in the serum of diabetics.

Metformin and lipid metabolism
Most studies on the mechanism by which metformin treats diabetes have been
focused on the liver. In hepatocytes, metformin activates AMPK, which regulates lipid
and glucose metabolism [43]. The activation of AMPK in the liver produces a reduction
in the activity of acetyl-CoA carboxylase (ACC), which is used to convert acetyl-CoA
into triglycerides, and also increases fatty acid oxidation (breakdown of fatty acids into
acetyl-CoA in the mitochondria to produce energy), which results in a reduction in lipids
stores [43]. It is known that many cancer cell types have high levels of de novo fatty acid
synthesis which participates in cell proliferation and cell survival, including that of
prostate cancer [44]. Therefore, a reduction in the lipid stores can affect the cancer cells
that are characterized by a high lipogenic metabolism, reducing their activity and
expression of oncoproteins [45].
AMPK activation also inhibits the mammalian target of rapamycin (mTOR), a
protein that participates in the control of cell energy expenditures by the regulation of
protein synthesis, cell growth, and autophagy. Activation of the mTOR pathway
promotes tumor growth in several cancer types; its activation correlates with cancer
progression, adverse prognosis, and chemotherapy resistance [40]. Thus, the inhibition of
mTOR by metformin via AMPK can be one possible pathway for the antiproliferative
effect of metformin, according to studies related with renal and breast cancer [39, 40]. In
addition, in vitro experiments using human THP-1 macrophages have shown that
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metformin reduced intracellular lipid accumulation and reduced the expression of fatty
acid-binding protein 4 (FABP4), a protein which functions in fatty acid uptake.
Interestingly, this protein is also expressed by PC-3 prostate cells [46, 47].

Metformin, prostate cancer, and PEDF
The effect of metformin on prostate cancer cells has been studied, showing that
metformin reduced cell proliferation in LNCaP, DU145, and PC-3 cells [48-50]. The
main drawback of these studies is that the authors used high doses of metformin on a
small number of cells. Moreover, they used colorimetric assays [48, 50] to evaluate cell
proliferation or viability instead of a direct cell counting method. In one of these
published studies, the authors showed that metformin at 1 and 5 mM doses reduced cell
proliferation in LNCaP, DU145, and PC-3 prostate cancer cells [50]. They found that the
5 mM metformin dose inhibited cell proliferation in LNCaP and DU145 prostate cancer
cell lines by blocking the G0/G1 phase during the cell cycle, which correlated with a
diminution of the cyclin D1 levels, which is required in the G1 phase [50]. This activity
was not seen in PC-3 cells.
Furthermore, the authors found that metformin activated AMPK in all three
prostate cancer cell lines. However, they found, using siRNA against AMPK, that the
anti-proliferative effect of metformin was still present in DU145 and LNCaP cells [50].
This suggests that AMPK is not the pathway for the antiproliferative effect of metformin
at these doses. A caveat of the above studies is that it is not possible to achieve 1 and 5
mM levels of metformin physiologically in human patients. Current prescribing
information indicates that metformin is recommended in doses in the range of 500 mg to
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2000 mg once daily, reaching plasma levels of approximately 0.6-1.8 µg/mL (NDA 20357/S-031, NDA 21-202/S-016). Thus, the highest physiologic concentration expected
for metformin is around 10.8 µM. Therefore, the use of physiologically obtainable doses
of metformin is a critical point to study the effect of metformin in humans.
In other cell types, PEDF has been shown to decrease cyclin D1 levels in other
cell types [17]. Another published study reported an increase in serum levels of PEDF in
newly diagnosed type 2 diabetes patients after metformin treatment. In this study, 36 type
2 diabetes patients received a dose of 850 mg of metformin twice a day. After six months,
serum PEDF levels of patients on metformin were significantly higher than those in
patients who were not on metformin [51]. This study supports a relationship between
metformin and PEDF. Thus, it is possible that metformin exerts its anti-proliferative
effect through induction of PEDF expression with a consequent reduction of cyclin D1
and/or lipid metabolism. The effects of PEDF on lipid metabolism have not been studied
in prostate cancer cells. Determining if metformin activity works in part through PEDF
could potentially open new possibilities to anticancer treatments targeting this pathway.
Thus, the above studies led to my hypothesis that metformin exerts its anti-proliferative
and lipid-regulatory functions in part via inducing PEDF expression in prostate cancer
cells. In order to support the hypothesis, the following specific aims were evaluated:

Specific aim 1. Elucidate if metformin mediates its anti-proliferative activity through
PEDF in the presence or absence of lipid overload by:
a) Quantifying PEDF level in metformin with or without OA treated prostate cells;
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b) Assessing levels of cyclin D1 and activated AMPK in metformin with/without
OA treated cells; and
c) Establishing if anti-PEDF siRNA treatment blocks metformin’s anti-proliferative
effect.
Specific aim 2. Examine if metformin regulates lipid metabolism in prostate cancer cells
by:
a) Assessing lipid levels qualitatively [oil red O (ORO) staining technique] and
quantitatively (direct triglyceride quantification) in metformin treated cells with
and without OA treatment;
b) Quantifying the lipolytic activity in samples from 2a; and,
c) Examining the levels of lipolytic activity in explant cultures of prostate tissues
from wild type versus PEDF knockout mice and quantifing triglyceride levels in
these tissues.
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MATERIALS AND METHODS
Cell lines and culture conditions
DU145, PC-3, LNCaP, and RWPE-1 cell lines were purchased from the American
Type Culture collection (ATCC, Manassas, VA). These cell lines are commonly used to
study prostate cancer. DU145 is a cell line that was isolated from a human prostate
adenocarcinoma metastasis to the brain [52]. PC-3 is a cell line that was obtained
originally from a human prostatic adenocarcinoma metastasis to bone [53]. LNCaP is
from a metastatic lesion of human prostatic carcinoma in lymph node [54]. RWPE-1 is a
normal adult human prostatic epithelial cell line, from a male donor, that has been
immortalized using human papilloma virus 18 [55]. The prostate cancer cell lines DU145
and PC-3 were grown in Dulbecco’s Modified Eagle Medium (DMEM, Sigma-Aldrich,
Saint Louis, MO, Cat.# D5796) with 10% fetal bovine serum (FBS, Sigma-Aldrich, Saint
Louis, MO, Cat # F2442) and 1% penicillin/streptomycin (P/S, Cellgro, Manassas VA,
Cat.# 30-002-Cl). The LNCaP cell line was grown in Roswell Park Memorial Institute
Medium (RPMI) medium with 10% FBS and 1% P/S. RWPE-1 cells were grown in
keratinocyte complete media with 1% P/S (Cellgro, Manassas VA, Cat.# 30-002-Cl). The
cells were all grown at 37°C and 5% CO2.

In Vitro obesity experiment using oleic acid
For in vitro experiments, cells were plated at 20,000 cells/cm2 on tissue culture
dishes (10 cm dishes, 6 well plates or 2 well chamber slides) at 37°C, 5% CO2 overnight.
After incubation the growth medium was aspirated and the cells were washed with sterile
PBS. Then, treatment medias (Table 1), with metformin at different doses with or without
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1mM oleic acid (OA), were added to the cells. Metformin was purchased from SigmaAldrich (Saint Louis MO, Cat.# D150959), and a 1 M stock solution was prepared in
basal medium (0.0828 g/1mL). The solution was syringe filtered (0.22 µm) to sterilize
before use. Basal media alone served as the negative (baseline) control. The cells were
incubated in the treatments medias for 48 hours at 37°C, 5% CO2. OA (Sigma-Aldrich,
Saint Louis, MO, Cat.# 03008) was used to overload the cells with lipid (as occurs in
patients with obesity). After incubation, the conditioned media and the cell lysates were
collected to evaluate cellular proliferation, triglyceride accumulation, and PEDF levels.
Cells on chamber slides were stained for lipids as described below.
Table 1. Treatments groups for metformin experiments
ID of sample
Treatment group
ID of sample
Treatment group
1A
Untreated
1B
Untreated + OA
2A
Metformin 20 µM
2B
Metformin 20 µM + OA
3A
Metformin 0.5 mM
3B
Met 0.5 mM + OA
4A
Metformin 5 mM
4B
Met 5 mM + OA

Proliferation assay
After 48 hour treatments, cell proliferation was assessed by direct count in a
cellometer (Nexcelom-Bioscience Auto T4 plus cell counter, Lawrence, MA). Briefly,
the conditioned media were collected and placed on ice. The cells were washed one time
with PBS and trypsinized at 37°C until cells lifted off the plate, and cells were removed
and added to 3 ml growth media to stop trypsinization. Fifty µL of the trypsin/cell
solution were mixed with 50 µl of 0.4% trypan blue solution (Sigma-Aldrich, Saint
Louis, MO, Cat.# T8154) to allow assessment of cell viability. Twenty µl of this mixture
were placed in a cell of a counting chamber slide. The cell counting was carried out in
duplicate on the Cellometer per manufacturer’s instructions. The total cell number, live
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cell number, and cell viability for each count were recorded. To detect changes in cell
proliferation each treatment was compared with untreated.

Cell lysate collection
Cell lysates were used to determine PEDF, cyclin-D1, and AMPK levels after
treatment with metformin with or without OA. Once the cell proliferation assays were
performed, the cells collected were pelleted by centrifugation at 800-1000 x g for 8
minutes, and the supernatant was aspirated. Cell lysis buffer (1X, 350 µl, Cell Signaling,
Danvers MA, Cat.# 9803S) was added and mixed by pipetting. The cell mixture was then
incubated on ice for 5 minutes, and then vortexed for 15-30 seconds. The cell lysate
solution was then transferred to a microfuge tube and centrifuged at 14000 x g at 4°C for
10 minutes. The supernatant was collected into siliconized tubes. Samples were stored at
4°C for immediate use or at -80°C for long term storage.

Collection and concentration of conditioned media
The conditioned media (CM) collected above was centrifuged (800 x g for 8 min)
to pellet any cellular debris, and the CM was transferred to a new tube. If needed for a
lipolysis assay, an aliquot was taken out. Then, 50 μL of 1X protease inhibitor cocktail
(Sigma-Aldrich,

Saint

Louis

MO,

Cat.# P8340)

and 50 μL of 100 nM

phenylmethanesulfonyl fluoride solution (PMSF, Sigma-Aldrich, Saint Louis MO, Cat.#.
93482) were added for a final 1:100 dilution of protease inhibitor cocktail and 10 µM
PMSF. The conditioned media were concentrated using a Millipore ultra-15 centrifugal
filter device with a 3 kDa cutoff and 15 ml volume (Amicon Ultra, Billerica, MA, Cat #
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UFC900324). Briefly, the membrane of the device was pre-wet using 5 ml of sterile PBS
and a spin of 4000 g at 4°C for 10 minutes. The remaining PBS was removed, and the
conditioned medium was added to the membrane approximately 10 mL at a time and
spun at 4000 g approximately 30 minutes interval. The concentrating continued at 5-60
minute intervals until all media from samples were concentrated. The filtrate was
discarded after each spin and more conditioned medium was added. After the addition of
the entire conditioned medium, the concentrated conditioned medium was washed with 12 volume of PBS or until the phenol red color disappeared. The conditioned media were
concentrated approximately 10 fold (a 500 µL of volume from 5 ml of conditioned
medium). The concentrated conditioned media were transferred to a sterile siliconized
microfuge tube and stored at -80°C until needed.

Qualitative assessment of lipid accumulation
In order to assess lipid accumulation qualitatively, cells on chamber slides were
stained following the protocol of nova UltraTM Oil Red O (ORO) stain kit (IHC World,
Woodstock MD, Cat.# IW-3008). Briefly, the cells were plated onto chamber slides at
20,000 cells/cm2 as described above. For the RWPE-1 and LNCaP cells to enhance cell
attachment to the slides, the slides were pre-coated with a 0.1% solution of Difco gelatin
overnight at 4°C (Becton Dickinson, Sparks, MD, Cat.# 214340). After incubation, the
gelation solution was aspirated and the slides were washed once with PBS. Then, the
cells were plated and treated as described above. After 48 h of treatment, the media were
aspirated and the cells were rinsed once with PBS. The chamber cassette was removed
with a razor blade and the cells were fixed using 10% formalin for at least 10 minutes.
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The slides were rinsed 3 times with distilled water and then placed in pre-stain solution
for 3-5 minutes. Next, the slides were stained in pre-warmed ORO solution at 60°C for
10 minutes. Next, the slides were placed in differentiation solution for 3-5 minutes, and
rinsed 3 times with tap water. The slides were placed in Myer’s hematoxylin solution for
1 minute to stain cell nuclei. Slides were rinsed with distilled water once, and coverslips
placed over the cells using aqueous mounting medium (GBI Labs, Mukilteo, WA, Cat.#
E01-18). After staining, the lipids stained red and the nuclei stained pale blue. Changes in
lipid accumulation were evaluated under a microscope at 40X and photographed as a
record of the data.

Quantitative assessment of lipid levels
After metformin with/without OA treatments, one set of cell lysates for each cell
line was collected for quantification of triglyceride levels. The protocol for triglyceride
isolation used is a modification of the Folch technique [26]. Briefly, after the metformin
with/without OA treatments, the conditioned media were removed and the cells were
washed 3 times with 3-5 ml of cold PBS. The cells were trypsinized and transferred to 15
ml conical tubes using 2 volumes of growth media. The cells were centrifuged at 800 x g
for 10 min, the media were aspirated, and the cells were resuspended in 500 µL of PBS.
The cells were then transferred into 1.5 ml microfuge tubes, and each sample was
sonicated two times for 25 seconds at 40% amplitude (Sonics, Sonis Vibra Cell, model
No. VCX130PB, Newtown, CT,). The samples were then transferred to glass tubes and
1.90 ml of 2:1 CHCl3:MeOH was added. The samples were incubated 15 minutes at room
temperature (RT) and vortexed every 5 min. Next, 0.6 ml of CHCl3 and 0.5 ml of NaCl
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were added and then the sample was vortexed. The samples were spun at 1910 x g (4000
rpm) for 30 min at 4°C. The upper aqueous layer was aspirated and the protein disk was
removed. The samples were maintained on ice, and the organic phase was dried under
nitrogen gas. Each sample was resuspended in 60 µL of CHCl3, and 20 µL were
transferred in a new glass tube and dried again under nitrogen gas.
Fifteen µL of autoclaved mH2O were added to the 20 μL dried sample. To each
sample, 1 mL of triglyceride reagent (StanBio, Boerne TX, Cat.# 2201-030) was then
added. The mixture was vortexed and incubated 10 minutes at RT. A serial dilution of
triglyceride standard (StanBio, Boerne TX, Cat.# 2103-002) was prepared. Two hundred
µL of each sample and standards were placed in triplicate wells in a 96 well plate. The
plate was read on a plate reader (Bio-Tek, model KC4, Winooski, VT) at 500 nm.
Triglyceride levels were determined by comparison to the standard curve. Data were
normalized to total cell number (for cells) or tissue weights (for prostate tissues;
described below).

Collection of mouse prostate tissues secretions.
Mouse prostate tissues were obtained following the general procedures
established by Dr. Doll (described below) and approved by the Institutional Animal Care
and Use Committee of the University of Wisconsin-Milwaukee. The ventral, anterior, and
dorsolateral lobes prostates from the wild type (n=5) and PEDF-KO (n=5) mice were
collected in order to determine lipolytic activity and the triglyceride content of the mouse
prostate for each strain. Briefly, the mouse was anesthetized with isoflurane inside a
desiccator jar. After anesthesia, the mouse was euthanized by cervical dislocation and
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placed in a dorsal position. Next, using sterile scissors and forcep, a midline incision was
made through the abdominal wall and peritoneum. The intestines were moved to side to
reveal the reproductive system. Finally, the anterior, ventral and dorsolateral lobes of the
prostate were excised under a dissecting microscope. Tissues were either immediately
frozen in liquid nitrogen or placed on ice for explant culture.
For explant culture, the weight of each prostate lobe was recorded. Then each
tissue was transferred to a 10 cm tissue culture dish and washed 3 times with 1 ml of
PBS. For dissection of tissues, sterile forceps, scalpel blades, or scissors were used. The
tissue was dissected in 1-2 mm pieces and placed in a well of a 6 well plate with 1 ml
basal media (DMEM). The plate was incubated at 37°C with 5% CO2 for 48 hours. After
incubation, the conditioned media were collected. The conditioned media were used in
the lipolysis assay, as described below.
For the triglyceride quantification, each tissue was weighed and placed in a glass
tube, washed with PBS, and homogenized with 300 µL of 2:1 CHCl3:MEOH solution
using a Kontes motor and disposable pestles (Fisher Scientific, Waltham, MA, Pestles
KT-749521-1590, Kontes motor KT749540-0000). To each sample, 100 µL of CHCl3
and 75 µL of NaCl were added and vortexed. The samples were then centrifuged at 1910
x g (4000 rpm) for 30 min at 4°C. The upper aqueous layer and protein disc were
aspirated. The samples were maintained on ice and the organic phase was dried using
nitrogen gas. Each sample was resuspended in 60 µL of CHCl3, and 20 µL were
transferred to a new glass tube and dried again under nitrogen gas. The dried samples
were used for the triglyceride quantification assay as described above.
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Quantification of lipolytic activity
The conditioned media from cell culture treatments and explant cultures were
used to quantify the lipolytic activity using the free glycerol assay (Sigma-Aldrich, Saint
Louis MO, Cat.# F6428). The levels of free glycerol released indicate the rate of
breakdown of triglycerides in the cell. Triglycerides are catabolized to a glycerol and
three free fatty acids. Thus, higher levels of free glycerol indicate higher rates of
lipolysis. This technique uses a free glycerol reagent that measures the free endogenous
glycerol using enzymatic reactions. This technique was performed with a slight
modification of the manufacturer’s protocol. Briefly, 800 µL of free glycerol reagent and
100, 200 or 400 µL of conditioned media were placed in a cuvette to be tested. The
volume depended on cell line as basal lipolytic levels varied between the cell lines. A
standard curve was generated using a glycerol standard (Sigma-Aldrich, Saint Louis MO,
Cat.# G7793). Assay blanks were prepared with glycerol reagent only. The absorbance
for each sample was read at 540 nm. The free glycerol levels were determined by
comparison to the standard curve. The data was normalized to total cell number (free
glycerol levels / total cell number) or tissue weight and compared to untreated as fold
over values.

Knockdown of PEDF expression using small interfering RNA (siRNA)
PEDF expression was blocked using siRNA to determine if metformin reduces
lipolytic activity and cell proliferation via PEDF in prostate cells. Four different siRNAs
directed against PEDF mRNA were tested (Thermo Scientific Dharmacon, Lafayette CO,
Cat.# J-010153-05, J-010153-06, J-010153-07, J-010153-08). Lipofectamine (Invitrogen,
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Van Allen Way Carlsbad, CA, Cat.# 11668-019) was used as the transfection reagent.
The procedure was executed following the general protocol indicated by the
manufacturer.
The cells were plated at 15,000 cells/cm2 in growth media and incubated at 37ºC
in 5% CO2 overnight. The siRNAs were prepared at 5, 10, 50 and 100 nM in order to find
the appropriate concentration to block PEDF expression. The siRNA and lipofectamine
mixes were incubated and room temperature for 5 minutes, and then the solutions were
prepared as indicated in Table 2, mixed, and incubated at RT for 20 minutes. The growth
media was aspirated from the cells, and 4.5 mL of fresh growth media without P/S was
added. The 500 µL of siRNA-lipofectamine mixture was then added and the cells were
incubated at 37ºC in 5% CO2 for 24 hours. After incubation, the transfection media were
removed. The cells were washed with PBS and incubated in basal media for 48 h. Cell
lysates and conditioned media were collected for analysis of PEDF levels. A non-specific
siRNA (Thermo Scientific Dharmacon, Lafayette CO, GAPDH, Cat.# D001810-01) was
included as a control for the siRNA transfection.
Table 2. Preparation of siRNA
siRNA mixture
Lipofectamine mixture
Concentration
Volume
Basal media
Lipofectamine (µL)
Basal media
siRNA (nM) siRNA (µL) without P/S
without P/S
(µL)
(µL)
5
1.25
98.75
6.25
393.75
10
2.5
975.5
12.5
387.5
50
12.5
87.5
62.5
337.5
100
25
75
125
275

Protein Quantification
Protein content in conditioned media and cell lysate samples was determined
using a standard Coomassie dye binding assay. The Coomassie reagent and pre-diluted
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protein standards were purchased from Thermo Pierce (Rockford, IL, catalog Nos.
1856209 and 23208). The standards were prepared as is indicated by the manufacturer.
The samples were either 10 µl of conditioned media or 5 µl of cell lysate + 5 µl of PBS.
The samples were added to 490 µl of Coomassie reagent. Then, the samples were
incubated for 5 min at RT. A volume of 200 µl was placed in duplicate wells on a 96 well
plate. The absorbance was read at 595 nm and the concentration was determined from the
standard curve.

Determination of PEDF levels by ELISA
PEDF levels were quantified by ELISA following the protocol provided by the
manufacturer (Bioproducts MD, Middletown MD, PEDF ELISA kit Cat.# PED613).
Briefly, the principle of the assay allows PEDF to bind to an antibody against the PEDF
antigen which is bound to the plate. This bound PEDF is detected by a second anti-PEDF
antibody conjugated with biotin. Streptavidin peroxidase is then added and this reacts
with biotin to produce a color. The optical density is proportional to the amount of PEDF
in the sample.
The PEDF antigen standard and all other reagents were prepared according to the
manufacturer’s directions. Briefly, 20 µg in a 100 μL volume of sample per well
(conditioned media or cell lysate) and 100 µl of standards were placed in duplicate wells.
The plate was covered and incubated at 37°C for 1 hour. Next, the samples were
aspirated, and the plate was washed with 1X wash buffer 5 times with the final wash
being aspirated. Next, 100 µL of PEDF detector antibody was added. The plate was then
covered and incubated at 37°C for 1 hour. The samples were aspirated and washed 5
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times, and then 100 µL of streptavidin peroxidase was added. The plate was covered and
incubated at 37°C for 30 minutes. Next, the samples were aspirated and washed 5 times.
Then, 100 µL of TMB substrate was added. The plate was incubated at room temperature
for 20 minutes, and then 100 µL of stop solution was added. The absorbance was read at
450 nm using plate reader (Bio-Tek, model KC4, Winooski, VT). The concentration of
PEDF in samples was determined by comparison to the standard curve. Values were
analyzed as foldover untreated.

Detection of cyclin D1 and AMPK by Western blot
The detection of cyclin D1 (MW=36 kDa) and AMPK (MW=62 kDa) was
performed by Western blot using antibodies against phosphorylated AMPK and cyclin
D1 (Cell Signaling Technology, Danvers, MA, Cat.# 2535 and 2922, respectively). Cell
lysate samples (40 µg/well) were prepared with 1X Laemmli sample buffer (BioRad,
Hercules, CA, Cat.# 161-0737), and were separated on a 12% acrylamide/Bis (29:1) premade gel (BioRad, Hercules, CA, Cat.# 456-1043). The samples were boiled for 10 min
prior to loading to ensure complete denaturation.
For Western blot hybridization, the membrane was blocked using 50 ml trisbuffered saline (TBS) with 5% powdered milk at RT for 1 hour. The membrane was
washed using TBS and then incubated with the first antibody diluted 1:1000 in TBSTween (0.1%) (TBS-T) + 5% bovine serum albumin (BSA; Sigma Aldrich, Saint Luis,
MO, Cat.# A6003) at 4°C overnight. The membrane was washed with TBS-T three times,
50 ml per wash, and then incubated with the secondary antibody (HRP conjugated)
diluted at 1:100-1:5000 in TBS-T + 5% BSA for 1 hour at RT. The membrane was
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washed with TBS-T three times, as described above. Next, enhanced chemiluminescence
(ECL) detection was performed using Super Signal West Pico chemiluminescent
substrate (Thermo Scientific, Rockford, IL, Cat.# 34080) for one minute. Next, the
membrane was placed protein side face up in a film cassette and covered with saran wrap.
In a dark room, the gel was exposed to X-ray film (Thermo Scientific, Rockford, IL,
Cat.#34093) from 1-5 minutes or longer as needed to obtain a useable exposure.
To probe with another antibody, membranes were stripped of antibody. The
membrane was washed with TBS-T and a 0.1% solution of SDS was boiled and then
poured on the membrane. The membrane was then cooled down to RT and washed again
with TBS-T. Finally, the membrane was rehybridized with the next antibody as described
above. For a control of protein loading between samples on the gel, membranes were
probed with antibodies against GAPDH (Cell Signaling, Danvers MA, Cat.# 7074. This
was performed on a stripped blot as described above.
Statistical methods
All the experiments were repeated at least twice. Dependent t-test was used in
order to determine changes in cell proliferation (total cell number and viability), PEDF
levels, free glycerol levels, and triglyceride levels during metformin with/without OA
treatments between each group and the control. ANOVA analysis was used in order to
determine dose response in cell culture experiments. All analyses were performed by the
statistical analysis software available within the Sigmaplot program (v12.0, Systat
Software, Inc, San Jose California). A result was considered significant when P≤0.05.
The data reported were normalized to total cell number or tissue weight and compared to
untreated as a fold over values.

26

RESULTS
The effects of OA with/without metformin on proliferation in prostate cell lines.
The effects of metformin have been previously studied in prostate cell lines. It has
been reported that metformin at 5 mM dose reduces cell proliferation in LNCaP, DU145,
and PC-3 cells [50]. However, these studies used a high dose of metformin which is not
possible to achieve in human patients. One of the main objectives of this research is to
test physiologically relevant doses of metformin. The 20 μM and 0.5 mM doses of
metformin are more physiologically relevant doses, and also the 5 mM dose was used in
order to compare the results of this research with the results reported in the literature. The
use of oleic acid (OA) to overload the cells with lipids is an innovate methodology used
to simulate a high fat diet in cancer cells (Doll, et al, unpublished data). In my research, I
also investigated if metformin blocks OA effects on prostate cell lines and if the PEDF
pathway is involved.
The first step was to evaluate metformin’s effect on cell proliferation in the
presence or absence of lipid overload. RWPE-1, LNCaP, DU145, and PC-3 prostate cell
lines were treated for 48 h with metformin at 20 µM, 0.5 mM, and 5 mM doses with or
without OA (1.0 mM). In RWPE-1 cells, OA treatment alone produced a slight, but not
significant, reduction in total cell number in comparison with untreated cells (Figure 1A).
Metformin treatment alone produced a significant increase in total cell number at 20 µM
(P=0.016) and 0.5 mM (P=0.012) doses, but, interestingly, metformin reduced the total
cell number at the 5 mM (P=0.048) dose; however, metformin with OA treatment did not
produce any significant changes in comparison with OA alone (Figure 1A). In the
viability assay, OA treatment alone reduced cell viability (P<0.001) in comparison with
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untreated cells (Figure 1B). Metformin treatment alone produced a significant reduction
in the 5 mM dose (P=0.012), and OA with metformin did not produce significant changes
at any dose in comparison with OA treatment alone (Figure 1B). The reduction of total
cell number and viability during metformin treatment at the 5 mM dose indicates that
metformin treatment of RWPE-1 cells produces a reduction of cell proliferation, possibly
by increasing cell death; but, at lower doses, metformin appeared to increase
proliferation.

Figure 1. The effects of OA with/without metformin on proliferation and cell viability in RWPE-1
cells. After OA with/without metformin treatments the cells were and incubated with 0.04% trypan blue
and (A) total cell number (significantly increased compared to untreated cells, P≤0.016;
significantly reduced compared to untreated cells, P=0.048) and (B) Viability were assessed
(significantly decreased compared to untreated cells, P<0.001; significantly decreased compared to
untreated cells, P=0.048). The results presented are the combined data of three experiments.

In the androgen-sensitive LNCaP cell line, the total cell number results showed
that OA treatment alone produced a slight increase in total cell number in comparison
with untreated cells which was not statistically significant (Figure 2A). Metformin
treatment alone did not produce a significant change in total cell number at any dose
(Figure 2A). OA with metformin increased total cell number at 20 µM (P=0.037) and 5
mM (P<0.001) in comparison with OA treatment alone (Figure 2A). In the viability
assay, OA treatment alone decreased viability (P<0.001) in comparison with untreated
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cells (Figure 2B). Metformin treatment alone did not produce a significant change at any
dose in comparison with untreated cells. OA with metformin significantly reduced
viability in a dose-dependent manner (ANOVA, P=0.002; Figure 2B). These results
suggest that metformin, in presence of OA, reduces viability of LNCaP cells.

Figure 2. Metformin + OA increase total cell number and reduces viability in LNCaP cells. Total
cell number and viability was determined in LNCaP cells after metformin with/without OA treatments.
(A) Total cell number was measured by direct cell counts on a Cellometer (significantly increased
compared to OA untreated cells, P<0.037). (B) Viability was determined on the Cellometer with trypan
blue exclusion assay (significantly decreased compared to untreated cells, P<0.001; significantly
decreased compared to OA untreated cells, P<0.034). The results presented are the combined data of
three independent experiments.

In PC-3 cells, OA treatment alone had no effect on total cell number in
comparison with untreated cells; however, it significantly reduced viability (Figure 3A).
Metformin treatments showed that metformin alone produced a significant decrease in
total cell number at 0.5 mM (P=0.035) and 5 mM (P<0.001) doses in comparison with
untreated cells (Figure 3A). In contrast, OA with metformin produced a no significant
increase in total cell number at 5 mM (P=0.059), in comparison with OA treatment alone
(Figure 3A). The results of the viability assay showed that OA alone reduced viability
(P<0.001) in comparison with untreated cells (Figure 3B). Metformin alone at any dose
did not produce significant change in comparison with untreated cells (Figure 3B).
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Similarly, metformin in combination with OA did not produce significant changes at any
dose in comparison with OA treatment alone (Figure 3B). These results indicate that
metformin in PC-3 cells reduces cell proliferation by reducing total cell number while
OA decreases viability.

Figure 3. Metformin reduces total cell number and OA decreases viability in PC-3 cells. Total cell
number and viability was determined in PC-3 cells after metformin with/without OA treatments. (A) Total
cell number was measured by direct cell counts on a Cellometer (significantly decreased compared to
untreated cells, P<0.035. (B) Viability was determined on the Cellometer with trypan blue exclusion assay
(significantly decreased compared to untreated cells, P<0.001). The results presented are the combination
of 2 experiments with similar results.

DU145 was the last cell line in which cell proliferation was evaluated. In the total
cell number, OA treatment alone produced a significant increase in comparison with
untreated cells (P<0.001), while metformin treatment alone produced a significant
reduction in proliferation at the 0.5 mM (P=0.008) and 5 mM (P=0.005) doses in
comparison with untreated cells (Figure 4A). The metformin activity demonstrated a
dose-dependent response (ANOVA P=0.006; Figure 4A). OA with metformin did not
produce significant changes at any dose in comparison with OA treatment alone (Figure
4A). The viability assay showed that OA treatment alone reduced viability significantly
in comparison with untreated cells (P<0.001; Figure 4B). Metformin treatment alone
produced a significant increase in viability at the 20 µM dose in comparison with
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untreated cells (P=0.027). Finally, OA with metformin reduced viability at 5 mM dose in
comparison with OA treatment alone (P=0.006; Figure 4B). These results indicate that, in
DU145 cells, metformin decreases cell proliferation by reducing total cell number since
cell viability is not changed, while OA reduced cell viability which was enhanced in the
presence of metformin at 5 mM dose.

Figure 4. Metformin reduces total cell number and OA reduces viability in DU145 prostate cancer
cells. Total cell number and viability was determined in DU145 cells after metformin with/without OA
treatments. (A) Total cell number was measured by direct cell counts on a Cellometer (significantly
increased compared to untreated cells, P<0.001; significantly decreased compared to untreated cells,
P=0.008. (B) Viability was determined on the Cellometer with trypan blue exclusion assay (significantly
decreased compared to untreated cells, P<0.001; significantly increased compared to untreated cells,
P=0.027; significantly decreased compared to OA untreated cells, P=0.006). The results presented are
the combined results of two experiments.

The cell proliferation assay results showed that metformin treatment alone
produced a reduction in total cell number in RWPE-1, PC-3, and DU145 cells, and
reduced viability in RWPE-1 cells. OA treatment alone increased total cell number in
DU145 cells, but, in combination with metformin, increased total cell number in LNCaP
cells. Otherwise, OA alone or in combination with metformin reduced viability in the
four cell lines.
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Effects of OA and metformin on lipid metabolism
Lipid accumulation by qualitative assay: The lipid accumulation, produced by
the OA treatment, was previously examined using Sudan black B staining in DU145 and
PC-3 cells which showed an increase in lipids with OA treatment (Doll, unpublished
data). This finding was validated using the neutral lipid-specific stain oil red O (ORO)
after OA treatments in all cell lines (Figure 5A-D). in all cell lines, basal levels of lipids
were low, and the addition of metformin treatment alone did not alter these levels (Figure
5A-D). In addition, metformin in the presence of OA in RWPE-1, LNCaP, and DU145
cells did not affect lipid accumulation (Figure 5A-C). However, in PC-3 cells, metformin
reduced the induced-lipid accumulation in a dose-dependent manner (Figure 5D).
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Figure 5. Metformin effect on lipid accumulation. RWPE-1, LNCaP, PC-3, and DU145 cell lines were
treated with OA with or without metformin. After treatments, the cells were stained with the neutral lipidspecific stain oil red O (ORO) technique. Lipids are stained red and nuclei are stained pale blue. In all cell
lines, OA treatment induced lipid accumulation (A-D). In RWPE-1 (A), LNCaP (B) and DU145 (C) cells,
metformin alone at any dose did not block lipid accumulation induced by the OA. (D) In PC-3 cells,
metformin reduced lipid accumulation during OA treatment. Each experiment was done twice with
similar results.
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Lipolytic activity: To evaluate if metformin affected triglyceride catabolism, the
lipolytic activity was evaluated by the quantification of free glycerol levels in the
conditioned media collected after OA with/without metformin treatments. In RWPE-1
cells, the free glycerol assay showed that OA treatment alone increased lipolytic activity
only slightly, and this was not significant, in comparison with untreated cells (Figure 6A;
P=0.108). Metformin treatment alone produced a significant increment in lipolytic
activity at 0.5 mM dose in comparison with untreated cells (P<0.001; Figure 6A).
Metformin alone, at 5 mM dose, slightly increased the lipolytic activity, but it was not
significant (P=0.111; Figure 6A). Otherwise, OA with metformin did not produce
significant reductions or increases in lipolytic activity at any dose in comparison with OA
treatment alone (Figure 6A).
In LNCaP cells, OA treatment alone did not affect the lipolytic activity. However,
metformin treatment alone significantly increased lipolytic activity at 0.5 mM and 5 mM
doses in comparison with untreated cells (P≤0.001; Figure 6B). Moreover, there was a
significant increase in lipolytic activity during OA treatment with metformin in a dose
response manner (ANOVA, P<0.001; Figure 6B).
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Figure 6. Metformin increases lipolytic activity in RWPE-1 and LNCaP cells. Free glycerol levels
were measured in conditioned media after OA with/without metformin treatments in (A) In RWPE-1 cells
(significantly increased compared to untreated cells, P<0.001) and (B) in LNCaP cells (significantly
increased compared to untreated cells, P<0.001;  significantly increased compared to OA untreated
cells, P<0.001). The results presented are the combined data of two independent experiments.

In DU145 cells, interestingly, OA treatment suppressed lipolytic activity
(P<0.001; Figure 7A). In contrast, metformin treatment alone significantly increased the
lipolytic activity at the 20 µM (P=0.025) and at the 0.5 mM (P=0.027) doses in
comparison to untreated cells (Figure 7A). OA with metformin at 5 mM dose produced a
significant increase in the lipolytic activity in comparison with OA treatment alone;
however, it was not big enough to overcome the reduction produced by the OA alone
(Figure 7A). The intracellular content of triglycerides was also determined in DU145
cells in order to quantitatively evaluate the lipid content. In DU145 cells, as expected,
OA treatment alone significantly increased triglyceride levels in comparison with
untreated cells (P=0.025, Figurem7B). Metformin treatment alone did not significantly
change triglyceride levels at any dose, in comparison with untreated cells (Figure 7B). In
contrast, metformin at 0.5 and 5 mM doses, in the presence of OA, reduced triglyceride
levels in comparison with OA alone; however, it did not reach significance at any dose
(Figure 7B).
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Figure 7: Metformin increases lipolytic activity in DU145 cells. (A) Free glycerol levels were
measured in conditioned media after metformin with/without OA treatment (significantly decreased
compared to untreated, P<0.001; significantly increased compared to untreated, P<0.027;
significantly increased compared to OA untreated, P=0.003). (B) Triglyceride levels were measured
in cell lysates after metformin with/without OA. Triglyceride levels (significantly increased compared
to untreated, P=0.025). The results presented in each graph are the combined results of two experiments

In contrast to DU145 cells, in PC-3 cells, OA stimulated lipolysis (P<0.001) in
comparison with untreated cells (Figure 8A). Moreover, metformin treatment alone did
not produce a significant change in lipolytic activity at any dose (Figure 8A). Also,
metformin did not alter the effect of OA on lipolytic activity (Figure 8A). As expected,
when triglyceride levels were determined, OA alone increased triglyceride levels in PC-3
cells (P=0.025; Figure 8B). Interestingly, in PC-3 cells, the metformin treatment alone
significantly increased triglyceride content at 0.5 mM and 5 mM doses in comparison
with untreated cells (P<0.001); but, OA with metformin reduced triglyceride levels in a
dose manner response (ANOVA, P<0.001; Figure 8B). This observation is consistent
with the reduction in the lipid accumulation observed in the ORO assay (Figure 5D).
These results suggest that metformin blocks lipid accumulation in PC-3 cells by reducing
the lipid uptake. In summary, the observation that all prostate cancer cell lines responded
differently to both the OA and metformin treatment is very interesting. It suggests that
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genetic differences between the cell lines likely have a significant impact on the
functional pathways affected by these treatments.

Figure 8. Metformin reduces triglyceride levels in PC-3 cells. (A) Free glycerol levels were measured
in conditioned media after metformin with/without OA treatment (significantly increased compared to
untreated cells, P<0.001). (B) Triglyceride levels were measured in cell lysates after metformin
with/without OA (significantly increased compared to untreated cells, P<0.001; significantly increased
compared to untreated cells, P<0.001; significantly decreased compared to OA untreated cells,
P<0.001). The results presented are the combined results of two experiments.

Determination of PEDF levels during OA with or without metformin treatments
In order to determine if metformin regulates PEDF levels, the levels of PEDF
were measured in cell lysates and conditioned media collected from the four cell lines
after OA with/without metformin treatments. Both the lysate and conditioned media were
examined because, while PEDF has primarily been studied as a secreted protein, there is
also a cytoplasmic pool of PEDF. Not surprisingly, based on the data obtained thus far,
results varied by cell line as well as between the conditioned media and cell lysate for
each line.
In the cell lysates of RWPE-1 and PC-3 cells, metformin treatment alone at any
dose did not produce significant change in PEDF levels (Figure 9A-B). In DU145 cells
metformin produced a dual effect, it produced a significant reduction of PEDF levels at
the 20 µM dose (P=0.025), and a non-significant increase at the 5 mM dose (P=0.270) in
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comparison with untreated cells (Figure 9C). In LNCaP cells, metformin treatment alone
increased PEDF levels at the 5 mM (P<0.001) dose in comparison with untreated cells
(Figure 9D). OA treatment alone did not produce significant change in PEDF levels in
RWPE-1, PC-3, and LNCaP cells (Figure 9A,B,D). However, in DU145 cells, OA
treatment decreased PEDF levels significantly in comparison with untreated cells
(P=0.007; Figure 9C). OA with metformin did not affect PEDF levels in any cell line at
any dose in comparison with OA treatment alone (Figure 9A-D).

Figure 9. Metformin with or without OA effect on intracellular PEDF levels. After metformin
with/without OA treatments, cell lysates were collected and PEDF levels were measured by ELISA. In
RWPE-1 (A) and PC-3 (B), metformin with/without OA treatments did not produce significant changes at
any dose. In DU145 cells (C), metformin and OA significantly reduced PEDF levels (Significantly
decreased compared to untreated, P=0.025; significantly decreased compared to untreated, P=0.007). In
LNCaP cells (D), metformin treatment alone increased PEDF levels (Significantly increased compared
to untreated, P<0.001). The results presented are the combined data of two independent experiments.
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In striking contrast to the variable results seen in the cell lysates, assays of the
conditioned media showed that OA consistently suppressed secreted PEDF levels in all
cell lines (P<0.05; Figure 10A-D). In RWPE-1 and LNCaP cells, metformin treatment
alone, at the 0.5 mM dose, induced a significant increase in PEDF levels in comparison
with untreated cells (P≤0.003, Figure 10A,C). Otherwise, metformin induced a reduction
in PEDF levels in RWPE-1 cells at the 5 mM (P<0.001) dose and in PC-3 cells at the 0.5
mM (P=0.010) dose in comparison with untreated cells (Figure 10A,B). OA with
metformin did not produce a significant change in PEDF levels in any cell line in
comparison with OA treatment alone (Figure 10A-D). These results suggest that OA may
selectively regulate secreted PEDF levels versus intracellular PEDF.
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Figure 10. OA treatment suppressed secreted PEDF levels while metformin had little impact. After
metformin with/without OA treatment the conditioned media were collected and PEDF levels were
measured by ELISA. OA reduced PEDF levels in the four cell lines. Metformin alone increased PEDF
levels in RWPE-1 and LNCaP cells. Metformin with OA did not produce significant changes at any dose
in comparison with untreated. (A) RWPE-1 cells (Significantly increased compared to untreated,
P=0.002;  significantly reduced compared to untreated, P<0.001; significantly reduced compared to
untreated, P<0.001). (B) PC-3 cells (Significantly reduced compared to untreated, P=0.010;
significantly reduced compared to untreated, P<0.001). (C) LNCaP cells (Significantly increased
compared to untreated, P=0.003; significantly reduced compared to untreated, P<0.001). (D) DU145
cells (Significantly reduced compared to untreated, P<0.001). Metformin increased extracellular PEDF
levels in RWPE (A) and LNCaP (C) cells. The results presented are the combination of two independent
experiments

Anti-PEDF siRNA treatment to block PEDF expression
The next step, in order to establish that PEDF plays a direct role in metforminresponse in prostate cells, would be to block PEDF expression and determine if the
response to metformin is lost. The DU145 cell line was used to test anti-PEDF siRNAs.
Four different anti-PEDF siRNA (PEDF 5, 6, 7, and 8) at 3 different doses (10, 50, and
100 nM) were used and mixed with lipofectamin to facilitate the transfection. After
treatment with the siRNAs, the conditioned media and cell lysates were collected, and
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PEDF levels were measured by ELISA. The non-targeting control siRNA had no effect
on PEDF levels in either the cell lysates or conditioned media. In conditioned media, the
anti-PEDF siRNA number 8 presented the best inhibition of PEDF at 50 nM (P=0.007)
and 100 nM (P=0.010) doses in comparison with untreated cells (Figure 11A). However,
the inhibition was only 40% compared to untreated cells, and it is recommended that at
least 80% inhibition be achieved in order to continue any test with siRNAs. In the cell
lysates, there was no significant PEDF inhibition with any of the anti-PEDF siRNA at
any dose (Figure 11B). Thus, further optimization or different anti-PEDF siRNAs are
needed to inhibit PEDF sufficiently. Interestingly, these observations suggest that there
may be different mRNAs that are transcribed to produce the two different pools of PEDF.
Also of interest, the regulation by the siRNA was similar to OA treatment, where secreted
PEDF levels were suppressed while cellular PEDF levels were not. Together, these data
suggest that PEDF regulation may be more complex than originally expected.

Figure 11. Use of anti-PEDF siRNA inhibits PEDF expression in DU145 cells. Four different antiPEDF siRNA were tested for inhibition of PEDF expression, PEDF-5, -6, -7, and -8. (A) In conditioned
media the anti-PEDF siRNA #8 presented the biggest inhibition (Significantly reduced compared to
untreated, 50 nM P=-0.007, 100 nM, P=0.010). (B) In cell lysates none of the anti-PEDF siRNA produced
inhibition compared to untreated. The results presented are the combined results of two experiments.
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Lipolytic activity and triglyceride content in wild type versus PEDF KO prostate
tissue
In order to extrapolate the research carried out in the in vitro experiments to in
vivo activity, the lipolytic activity and the triglyceride content were determined ex vivo in
wild type and PEDF KO prostate tissues. The dorsolateral left prostate of wild type and
PEDF KO mice (n=5 per group) were used to measure the free glycerol levels. The PEDF
KO mice presented with a reduced lipolytic activity in comparison with the wild type
tissues; however, this was not statistically significant (P=0.153; Figure 12). Based on the
trend of decreased lipolytic activity observed in the PEDF KO tissues, future studies
should analyze additional mice to determine if a true difference exists. In addition, all
lobes of the mouse prostate should be analyzed to establish if there is a difference
between lobes.

Figure 12. Loss of PEDF may reduce lipolytic activity in prostate tissue. Free glycerol levels were
measured in dorsolateral prostate tissues (left lobe) collected from wild type and PEDF KO mice (n=5
each group). Tissues were minced for explant culture and lipolytic activity was measured in the serumfree conditioned media using the free glycerol assay. The difference between the wild type and PEDF KO
activity was not significant (P=0.153).
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Triglyceride levels were quantified in the ventral, dorsolateral right lobe, and
anterior prostate lobes of wild type and PEDF KO mice (n=5 per group). Values were
normalized per gram of weight of tissue, and, interestingly, each prostate lobe showed
different triglyceride content (Figure 13). The ventral prostate of the PEDF KO mice
presented higher levels of triglycerides in comparison with the wild type tissues. In the
dorsolateral right lobe, PEDF KO mice had a slightly reduced triglyceride content in
comparison to wild type tissues, while in the anterior prostate lobe, triglyceride levels
were similar in both mouse strains (Figure 13). While the data obtained in the mouse
studies were not significant, the trends observed suggest that further studies, to increase
the number of animals analyzed, are warranted to determine if true differences exist.

Figure 13. Effect of PEDF loss on triglyceride content in prostate tissues. Triglyceride levels were
measured in wild type (WT) and PEDF KO prostate tissues. PEDF KO ventral prostate presented higher
content of triglycerides in comparison with WT (P=0.356). PEDF KO-dorsolateral right prostate presented
a lower content of triglycerides than WT (P=0.345). PEDF KO and WT anterior prostate presented similar
triglyceride levels (P=0.690).
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DISCUSSION
The purpose of this thesis was to determine if the anticancer effect of metformin
is mediated in part via PEDF. Metformin is a drug used by diabetic patients to control
their sugar levels. Several studies have shown that diabetic patients on metformin present
a reduction in incidence and progression of different cancers, including prostate cancer
[35, 36, 39, 41]. Also, it has been reported that metformin reduces cell proliferation in
LNCaP, DU145, and PC-3 prostate cell lines [50]. The mechanism of action of
metformin has been studied on prostate cancer cells, however, its mechanism of action
remains unclear. It is possible that in prostate cancer cells, different pathways are
involved. For example, in LNCaP and DU145 cells metformin blocked G0/G1 phase, with
a reduction of cyclin D1, to produce a reduction in cell proliferation or viability [50]. In
other cancer cell types, activation of AMPK has been demonstrated [39, 40, 43].
However, in prostate cancer cells metformin induction of AMPK did not seem critical
[50]. Metformin could also increase lipolysis and reduce lipogenesis, affecting the lipid
stores that are needed for cellular processes.
I hypothesized that PEDF may mediate metformin’s activity in prostate cancer
cells. A published study showed that diabetic PCa patients on metformin presented with
higher serum PEDF levels in comparison with non-diabetic patients not on metformin
[51]. Moreover, a previous experiment found, using immunohistochemistry, that
metformin increased PEDF levels in prostate cancer cells (Doll, unpublished data). The
results of my experiments thesis showed that metformin produced different effects among
the prostate cell lines used, depending on if it was administrated alone or in combination
with OA. In general, metformin treatments showed a decrease in cell proliferation,

44

increase in lipolytic activity. Also, metformin induced a slight increase in PEDF levels of
RWPE-1 and LNCaP cells. These results suggest that a signal pathway for metformin
activity is in part through PEDF expression. Therefore, the following specific aims were
studied to support my hypothesis.

Specific aim 1. Elucidate if metformin mediates its anti-proliferative activity through
PEDF in the presence or absence of lipid overload by:
a) Quantifying PEDF level in metformin with or without OA treated prostate cells;
b) Assessing levels of cyclin D1 and activated AMPK in metformin with/without
OA treated cells; and
c) Establishing if anti-PEDF siRNA treatment blocks metformin’s anti-proliferative
effect.

The first step was to evaluate the effect of several doses of metformin on cell
proliferation and viability in prostate cancer cells (LNCaP, DU145, and PC-3) and a
normal prostate epithelial cell line (RWPE-1). In a study by Sahra, et al, it was reported
that metformin reduced cell proliferation by approximately 50% in LNCaP, DU145, and
PC-3 cells [50]. The authors tested metformin at 5 mM dose and 3 days later the cell
proliferation was determined using the MTT assay. That study presents the drawback that
the authors used a high dose of metformin which is not physiologically possible to reach
in humans. The actual doses of metformin that are recommended in diabetic patients are
500-2000 mg per day; thus, the highest plasma concentration would be 10.8 μM (NDA
20-357/S-031, NDA 21-202/S-016). In addition, the authors assessed proliferation using
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the MTT assay, a metabolic assay which functions as an indirect indicator of cell
proliferation. The MTT assay is based on the ability of living cells to convert the MTT
reagent into formazan crystals. This works as an indicator of mitochondrial activity
which is directly related with the number of living

cells [56]. However, it is

recommended to use direct cell counting to determine live cells together with the MTT
assay because metformin is known to increase the activity of the mitochondria to increase
the fatty acid oxidation [43]. Thus, the MTT could not be accurate. The cell proliferation
experiments presented here were performed using direct cell counts with trypan blue
exclusion assay to obtain total cell numbers and viability data.
The cell proliferation data showed that metformin treatment alone significantly
reduced total cell number in RWPE-1 (at 5 mM dose), PC-3 (at 0.5 and 5 mM doses), and
in DU145 (at 0.5 and 5 mM doses) cells. Moreover, metformin treatment alone did not
reduce viability in LNCaP, PC-3, or DU145 cells, at 20 µM, 0.5 mM, or 5 mM doses.
However, there was a reduction in viability in the RWPE-1 cells with metformin at the 5
mM dose. The differences in the results between cell lines in my data and between my
results and published studies [48-50] could result from several factors. In the published
studies, the authors plated fewer cells/cm2 and assayed after three days of treatment with
1 mM metformin. Thus, this high dose of metformin on the cell lines for three days might
reduce cell proliferation more than the two days treatment that I performed. Also, the
MTT assay was carried out in 96 well plates; thus, the use of a smaller platting surface
combined with using a metabolic assay may also account for the contrasting results as
well since 10 cm dishes were used in my studies.
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One likely explanation for the differences that I observed in response to treatment
between cell lines in my studies is the genetic background of the cell lines. Many studies
have described genetic differences among the prostate cancer cells lines commonly used
in prostate cancer research studies [57-62]. The presence or absence of different gene
products within each of the cell lines during treatment could be the basis of the observed
differences in the results. Table 3 indicates some of the key genetic differences present
among prostate cell lines. For example, p53 and Rb genes control cellular senescence.
Interestingly, the four cell lines present different patterns of expression in these two
genes. Moreover, my cell proliferation data showed that each cell line presented a
different response after metformin and OA treatments. Based on this information, the
differences in the expression of p53 and Rb could, in part, explain the differences
observed in the cell proliferation assays. Similarly, the differences in the expression of
tumor suppressor genes and oncogenes among the cell lines could also impact the lipid
metabolism, such as the lipolytic activity, in each cell line.
Table 3. Genes commonly altered in the prostate cell lines used in this study.*
Gene name
RWPE-1
Tumor suppressor genes
PTEN
Wildtype
P53
Null
Rb
Null
Oncogenes
Bcl-2
Wildtype
c-myc
Null

LNCaP

DU145

PC-3

Mutant
Wildtype
Wildtype

Wildtype
Mutant
Mutant

Null
Null
Wildtype

Wildtype
Null

Null
Wildtype

Wildtype
Wildtype

Key: Wildtype, produces a normal, functional protein; Null, produces no protein; Mutant, produces a non-functional
protein.
*Information based on [57-62]

It has been shown that OA treatment increases cellular proliferation in DU145 and
PC-3 cells lines using MTT assays and direct cell counts with trypan blue exclusion
(Doll, unpublished data). However, my data showed that OA treatment alone
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significantly increased total cell number just in DU145 cells, and OA with metformin
significantly increased total cell number in LNCaP cells. A consistent finding was that
OA reduced viability in the four cell lines. Similarly, OA with metformin further reduced
the viability in LNCaP and DU145 cells. Thus, my results show that metformin reduces
cell proliferation by reducing total cell number or viability depending if is administrated
alone or in combination with OA.
The Ben Sahra, et al, study showed that cyclin D1 was decreased in DU145 cells,
but not in PC-3 cells, after metformin treatment at 5 mM [50]. To examine this in my
samples, I performed Western blots of DU145 and PC-3 cells. These showed that the
expression of cyclin D1 is still present at 20 μM and 0.5 mM doses of metformin, and the
reduction of cyclin D 1 was only observed at 5 mM dose (data not shown). While this
does correlate with the published study, it also suggests that during the expression of
cyclin D1 at 20 μM and 0.5 mM doses of metformin alternative mechanisms are involved
to reduce cell proliferation. A caveat to this, however, is that a blot with a house keeping
gene to normalize the cyclin D1 expression was not obtained; thus, the studies have to be
repeated before a conclusion can be reached.
Another potential mechanism to explain the antiproliferative effect of metformin
is the activation of AMPK. Metformin has been shown to activate AMPK in hepatocytes
which decreased acetyl CoA carboxylase and increased fatty acid oxidation [43]. This
activity produces an overall reduction in the fatty acid stores available in the cell. Ben
Sahra, et al, found that metformin at 5 mM dose produces an upregulation of AMPK in
LNCaP, DU145, and PC-3 cells [50]. Moreover, they found that the inhibition of AMPK
did not affect the anti-proliferative effect of metformin at the 5 mM dose [50]. Thus, the
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authors indicated that AMPK was not necessary for the metformin effect in the prostate
cell lines studied. To see if this can be applied to lower doses of metformin, the AMPK
activation was examined among the samples in. My Western blot data showed that
AMPK was activated by metformin in at the 0.5 and 5 mM doses in DU145 and PC-3
cells (data not shown); however, at the 20 µM dose, there appears to be a decrease of
AMPK. Again, however, these observations have the caveat that normalization to a
housekeeping gene was not done. So, while no firm conclusions can be drawn, these data
are consistent with my observations of triglyceride levels in the cells. For example, in
PC-3 cells the increased expression of AMPK during metformin with OA treatment is
consistent with the reduction in the triglyceride levels. Also, the upregulation of AMPK
is consistent with the increase in the lipolytic activity in DU145 cells. This suggests that
this lipid regulatory function could participate in the reduction of cell proliferation. To
investigate this, future experiments would need to block lipolytic activity or to
overexpress cyclin D1 to determine which ameliorates metformin’s activity.
The experiments showed that metformin produced an increase in intracellular
PEDF levels in RWPE-1 and LNCaP cells. Moreover, the OA treatment reduced
extracellular PEDF in all four of the cell lines tested, and the addition of metformin did
not overcome the effect of OA. In addition, the fact that OA reduces extracellular PEDF,
but does not reduce intracellular PEDF, suggests that there may be different mechanisms
regulating the two PEDF pools such as the production of two different mRNAs from the
PEDF gene. In fact, it has been reported that different isoforms of PEDF are produced,
each one with different properties [63]. Thus, it is possible that each PEDF isoform
participates in different cellular processes. For example one could participate in lipid
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metabolism activities such as the reduction of lipid accumulation (PC-3 cells), or lipolytic
activity (RWPE-1, LNCaP, and DU145 cells). Another PEDF isoform might participate
in the regulation of cell proliferation. Thus, future experiments to specifically compare
intra- and extra-cellular PEDF, as well as the PEDF mRNAs produced in the prostate cell
lines are needed.
In summary, the results for Aim 1 showed that: 1) PEDF is present in both the
cytoplasmic and secreted protein pools; 2) that metformin slightly increased PEDF levels
at different doses; and, 3) that OA reduced PEDF levels in the conditioned media of all
four cell lines. Thus, it is possible to propose that metformin has some stimulatory
activity on PEDF levels, but that this effect was not sufficient to overcome OA
suppression. Thus, a higher PEDF concentration might be needed in order to overcome
changes in the lipid metabolism in the presence of lipid overload. Also, it seems possible
that the reduction of secreted PEDF levels produced by OA is related to the reduction in
lipolytic activity. Therefore, studies blocking PEDF during metformin and OA treatment
are needed.
In this point of my investigation, the inhibition of PEDF during metformin
treatment would test if PEDF participates in metformin’s activity and the regulation of
cyclin D1 and AMPK in prostate cells. In an attempt to do this, I tested four different
anti-PEDF siRNAs. DU145 cell line was selected because it showed reduction in cell
proliferation and active lipolytic activity during metformin with/without OA treatments.
The use of the anti-PEDF siRNA #8 in DU145 cells showed inhibition of 40% in
comparison with untreated cells. However, at least an 80% inhibition is required to
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continue any cellular siRNA assay. Thus, future experiments are necessary to optimize
this assay and determine if the participation of PEDF is required for metformin’s activity.

Specific aim 2. Examine if metformin regulates lipid metabolism in prostate cancer cells
by:
a) Assessing lipid levels qualitatively (ORO staining) and quantitatively (direct
triglyceride quantification) in metformin treated cells with and without OA
treatment;
b) Quantifying the lipolytic activity in samples from 2a; and,
c) Examining the levels of lipolytic activity in explant cultures of prostate tissues
from wild type versus PEDF knockout mice and quantify triglyceride levels in
these tissues.
The effects of metformin on lipid metabolism (Specific aim 2a,b) has not been
studied in prostate cells. The first step to evaluate the role of metformin on lipid
metabolism was by the ORO assay after metformin with or without OA treatments. In my
experiments, metformin did not reduce lipid accumulation in RWPE-1, LNCaP, and
DU145 cells, but it did reduce lipid accumulation in PC-3 cells. It has been reported that
metformin treatment reduced lipid accumulation in macrophages due to a reduction of the
expression of fatty acid-binding protein 4 (FABP4) which participates in lipid uptake
[46]. This protein is also expressed on PC-3 cells [47], thus the result obtained in the
ORO assays suggest that this protein may participates in the lipid metabolism of PC-3
cells. Thus, future studies are needed to investigate the role of this protein in the
regulation of lipid uptake in PC-3 cells.
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It has been reported that metformin activates AMPK in the hepatocytes which
regulates lipid metabolism [43]. This AMPK activation increases fatty acid oxidation,
and a necessary step toward this, also induces lipolytic activity to produce free fatty acids
from triglycerides. The results for the specific aim 2b showed that OA alone produced a
significant reduction in lipolytic activity in DU145 cells and an increase in PC-3 cells.
Metformin treatment alone increased lipolytic activity in RWPE-1, LNCaP, and DU145
cells. Metformin in the presence of OA increased the lipolytic activity in RWPE-1,
LNCaP, and DU145 cells. These results show that the genetic differences among the cell
lines (discussed above) affect different pathways during metformin with or without OA
treatment. Thus, microarrays analysis of genes that are up- or down-regulated with
metformin treatments in the presence or absence of OA, would facilitate understanding of
how the genetic background of the cell lines affect response to this treatment.
Specific aim 2c was successfully carried out using prostate tissue of PEDF KO
mice. I anticipated that loss of PEDF would reduce lipolytic activity, and I did observe a
reduction in the dorsolateral prostate lobe although this did not reach statistical
significance. This result was consistent with the results obtained in vitro. Based on the
lipolytic activity in PEDF KO tissue, I expected an increase in the triglyceride levels in
the PEDF KO prostate tissues. However, just the PEDF KO ventral tissue presented with
an increase in triglyceride levels, although this also was not statistically significant. The
trends observed support the idea that PEDF regulates lipid metabolism in the prostate, but
additional tissues need to be examined in order to determine if the differences are
significant.
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CONCLUSION
The hypothesis of this investigation was that the antiproliferative effect of
metformin is in part mediated via PEDF. Two specific aims were addressed in order to
test the hypothesis. The specific aim #1 was to establish if the antiproliferative effect of
metformin was via PEDF in the presence or absence of lipid overload. The first set of
experiments tested the antiproliferative effect of metformin on prostate cell lines. In these
experiments physiologically relevant doses of metformin (20 μM and 0.5 mM) were
tested, which until now has not been reported in the literature. Moreover, the testing of
the effect of metformin in presence of lipid overload is also novel. My cell proliferation
data contrasted with previous published studies that indicate that metformin reduces cell
proliferation at 5 mM dose in LNCaP, DU145, and PC-3 cells [50]. My data showed that
metformin alone at 5 mM dose significantly reduced the viability in just RWPE-1 cells.
However, metformin alone reduced total cell number in PC-3 and DU145 cells. OA alone
reduced viability in the 4 cell lines. Metformin with OA reduced the viability in LNCaP
and DU145 cells, which suggests that in these cell lines, some pathways are activated to
reduce cell proliferation but possibly they are not activated in RWPE-1 and PC-3 cells.
Thus, my data showed that metformin possesses an antiproliferative effect that consists of
a reduction in total cell number and viability, and the reduction of viability is enhanced in
the presence of lipid overload. Due to technical difficulties with the siRNA inhibition of
PEDF, this sub-aim was not completed. Thus, future studies will seek to optimize siRNA
experiments to achieve PEDF suppression.
Specific aim 2 was focused on determining if metformin regulates lipid
metabolism in prostate cancer cells and if so, if this activity is mediated via PEDF. These
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studies are the first to examine the effects of lipid overload and metformin on prostate
cancer cells. The data showed that metformin increased lipolytic activity at different
levels depending on the cell line, dose, and if it was administered alone or in combination
with OA. Metformin treatment alone increased lipolytic activity in RWPE-1, LNCaP, and
DU145 cells. Metformin in combination with OA increased lipolytic activity in LNCaP
and DU145 cells. Also, it is important to point out that metformin, in the presence of OA,
reduced triglyceride levels in PC-3 cells, which is consistent with the reduction in lipid
accumulation observed in this cell line.
Based on these data, it was clear that metformin and OA treatments have an
impact on cell proliferation and lipid metabolism in prostate epithelial cells. The
measurement of intracellular and secreted PEDF levels during metformin with or without
OA treatments showed that PEDF is affected modestly by metformin, but that OA has a
more significant impact. Therefore, the reduction of PEDF during OA treatments may
impact metformin’s effect. Thus, future experiments blocking PEDF expression are
critical to evaluate its role during metformin treatments. As an alternative to evaluate the
effect of PEDF inhibition, I used the PEDF KO mouse prostate tissues as an ex vivo
model. The PEDF KO prostate tissues had somewhat reduced lipolytic activity in
comparison with WT. Moreover, the lack of PEDF affected the triglyceride levels among
the prostate lobes. However, these results were not statistically significant and additional
animals are needed to establish a real effect.
In summary, the work presented here supports a novel molecular pathway to
explain the antiproliferative effect of metformin on prostate cells. My data support my
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hypothesis that PEDF is involved in the metformin pathway. In addition, my data
demonstrate that metformin also regulates lipid metabolism in prostate epithelial cells.
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